Adding Novartis Drug Zometa® to Chemotherapy Significantly Improved Overall Survival in Study of Newly Diagnosed …
- Phase III data show Zometa, a bone-targeted agent, provided significant clinical anticancer benefit and significantly reduced risk of skeletal-related events read more

Read more on SYS-CON Media